drugset / Trial / NCT01983969
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
SequentialOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of azacitidine that can be given with vorinostat, gemcitabine, busulfan, and melphalan, with a stem cell transplant, and with or without rituximab. Researchers also want to learn about the safety and level of effectiveness of this combination.
Timeline
- Start
- 2013-11-07
- Primary completion
- 2017-11-22
- Completion
- 2017-11-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 15 mg/m2 | Intravenous |
| Subject | Busulfan | Small molecule | 32 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 22775 mg/m2 | Intravenous |
| Background | Dexamethasone | Small molecule | 8 mg | Intravenous |
| Background | Glutamine | Other / unclassified | 15 g | Oral |
| Background | Melphalan | Small molecule | 60 mg/m2 | Intravenous |
| Background | Pyridoxine | Unknown | 100 mg | Intravenous |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Vorinostat | Small molecule | 1000 mg | Intravenous |